BioAge Labs, a biopharmaceutical startup focused on obesity drugs, is looking to raise nearly $200 million in its recently ...

Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public ...

California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a ...

Weight-loss drug developer BioAge Labs (BIOA) on Wednesday announced the pricing of its upsized initial public offering of 11 ...

Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.

BioAge Labs has raised $198 million after pricing its upsized U.S. initial public offering at the midpoint of the targeted range at $18 per share, the weight-loss drug developer said on Wednesday.

The offering, which was upsized twice, will support development of a drug the company believes can boost the effects of ...

BioAge Labs (BIOA), which is developing a drug to augment popular weight-loss medications such as Wegovy and Zepbound, has upsized its proposed IPO. Read more here.

Obesity drug developer BioAge Labs (BIOA) files for U.S. IPO to offer 7.5M shares at $17-$19 implying valution of up to $602M ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of ...